NCT01336803 2023-12-27
Osteosarcoma
Stanford University
Phase 2 Completed
Clinical Trials
8 trialsNCT00978562 2022-08-03
DSC-MRI With Ferumoxytol and DCE-MRI With Gadolinium in Imaging Vascular Properties in Younger Patients With Brain Tumors
OHSU Knight Cancer Institute
Phase EARLY_PHASE1 Completed
NCT00103038 2022-06-09
Ferumoxytol in Improving MR Imaging in Patients With High-Grade Brain Tumors or Cerebral Metastases
OHSU Knight Cancer Institute
Phase NA Completed
NCT01815333 2020-10-19
Clinical and Technical Feasibility of a Ultrasuperparamagnetic Nanoparticle Iron Oxide (USPIO)-Enhanced Magnetic Resonance Lymph Node Imaging
M.D. Anderson Cancer Center
Phase NA Completed
NCT01770353 2019-11-27
MM-398 (Nanoliposomal Irinotecan, Nal-IRI) to Determine Tumor Drug Levels and to Evaluate the Feasibility of Ferumoxytol Magnetic Resonance Imaging to Measure Tumor Associated Macrophages and to Predict Patient Response to Treatment
Ipsen
Phase 1 Completed
NCT02141490 2019-09-06
Study of Ferumoxytol Enhanced MRI for Detecting Lymph Node Metastases in Prostate, Bladder, and Kidney Cancers
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT01927887 2017-06-06
Pre-Operative Nodal Staging of Thyroid Cancer Using USPIO MRI: Preliminary Study
Massachusetts General Hospital
Phase NA Completed
NCT00660543 2017-05-16
MRI Study With Ferumoxytol in Assessing Early Response in Patients With Glioblastoma Multiforme Receiving Temozolomide and Radiation Therapy
OHSU Knight Cancer Institute
Phase NA Completed